Literature DB >> 21391972

Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia.

Thomas Ernst1, Joannah Score, Michael Deininger, Claire Hidalgo-Curtis, Peter Lackie, William B Ershler, John M Goldman, Nicholas C P Cross, Francish Grand.   

Abstract

We have identified two novel ABL1 fusion genes in two patients with B-cell acute lymphoblastic leukaemia (ALL) associated with a t(3;9)(p12;q34) and a t(5;9)(q23;q34), respectively. Molecular analysis revealed a FOXP1-ABL1 fusion for the t(3;9) and a SNX2-ABL1 fusion for the t(5;9). The fusions were confirmed by specific amplification of the genomic breakpoints using reverse transcription polymerase chain reaction. The identification of ALL with rare ABL1 fusion partners is important because the leukaemia may respond to tyrosine kinase inhibitors in the same way as ALL patients with a classical BCR-ABL1 fusion gene.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21391972     DOI: 10.1111/j.1365-2141.2010.08457.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.

Authors:  Hervé Ghesquieres; Susan L Slager; Fabrice Jardin; Amelie S Veron; Yan W Asmann; Matthew J Maurer; Thierry Fest; Thomas M Habermann; Marie C Bene; Anne J Novak; Sylvain Mareschal; Corinne Haioun; Thierry Lamy; Stephen M Ansell; Herve Tilly; Thomas E Witzig; George J Weiner; Andrew L Feldman; Ahmet Dogan; Julie M Cunningham; Curtis L Olswold; Thierry Jo Molina; Brian K Link; Noel Milpied; David G Cox; Gilles A Salles; James R Cerhan
Journal:  J Clin Oncol       Date:  2015-10-12       Impact factor: 44.544

Review 2.  Updates on eosinophilic disorders.

Authors:  Alexandar Tzankov; Kaaren K Reichard; Robert P Hasserjian; Daniel A Arber; Attilio Orazi; Sa A Wang
Journal:  Virchows Arch       Date:  2022-09-07       Impact factor: 4.535

3.  Down-regulation of SNX1 predicts poor prognosis and contributes to drug resistance in colorectal cancer.

Authors:  Zehua Bian; Yuyang Feng; Yao Xue; Yaling Hu; Qifeng Wang; Leyuan Zhou; Zhihui Liu; Jiwei Zhang; Yuan Yin; Bing Gu; Zhaohui Huang
Journal:  Tumour Biol       Date:  2015-12-07

4.  Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

Authors:  Kathryn G Roberts; Yongjin Li; Debbie Payne-Turner; Richard C Harvey; Yung-Li Yang; Deqing Pei; Kelly McCastlain; Li Ding; Charles Lu; Guangchun Song; Jing Ma; Jared Becksfort; Michael Rusch; Shann-Ching Chen; John Easton; Jinjun Cheng; Kristy Boggs; Natalia Santiago-Morales; Ilaria Iacobucci; Robert S Fulton; Ji Wen; Marcus Valentine; Cheng Cheng; Steven W Paugh; Meenakshi Devidas; I-Ming Chen; Shalini Reshmi; Amy Smith; Erin Hedlund; Pankaj Gupta; Panduka Nagahawatte; Gang Wu; Xiang Chen; Donald Yergeau; Bhavin Vadodaria; Heather Mulder; Naomi J Winick; Eric C Larsen; William L Carroll; Nyla A Heerema; Andrew J Carroll; Guy Grayson; Sarah K Tasian; Andrew S Moore; Frank Keller; Melissa Frei-Jones; James A Whitlock; Elizabeth A Raetz; Deborah L White; Timothy P Hughes; Jaime M Guidry Auvil; Malcolm A Smith; Guido Marcucci; Clara D Bloomfield; Krzysztof Mrózek; Jessica Kohlschmidt; Wendy Stock; Steven M Kornblau; Marina Konopleva; Elisabeth Paietta; Ching-Hon Pui; Sima Jeha; Mary V Relling; William E Evans; Daniela S Gerhard; Julie M Gastier-Foster; Elaine Mardis; Richard K Wilson; Mignon L Loh; James R Downing; Stephen P Hunger; Cheryl L Willman; Jinghui Zhang; Charles G Mullighan
Journal:  N Engl J Med       Date:  2014-09-11       Impact factor: 91.245

Review 5.  Role of ABL family kinases in cancer: from leukaemia to solid tumours.

Authors:  Emileigh K Greuber; Pameeka Smith-Pearson; Jun Wang; Ann Marie Pendergast
Journal:  Nat Rev Cancer       Date:  2013-07-11       Impact factor: 60.716

6.  Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations.

Authors:  Jennifer A Oberg; Julia L Glade Bender; Maria Luisa Sulis; Danielle Pendrick; Anthony N Sireci; Susan J Hsiao; Andrew T Turk; Filemon S Dela Cruz; Hanina Hibshoosh; Helen Remotti; Rebecca J Zylber; Jiuhong Pang; Daniel Diolaiti; Carrie Koval; Stuart J Andrews; James H Garvin; Darrell J Yamashiro; Wendy K Chung; Stephen G Emerson; Peter L Nagy; Mahesh M Mansukhani; Andrew L Kung
Journal:  Genome Med       Date:  2016-12-23       Impact factor: 11.117

7.  Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.

Authors:  Judith M Boer; Elisabeth M P Steeghs; João R M Marchante; Aurélie Boeree; James J Beaudoin; H Berna Beverloo; Roland P Kuiper; Gabriele Escherich; Vincent H J van der Velden; C Ellen van der Schoot; Hester A de Groot-Kruseman; Rob Pieters; Monique L den Boer
Journal:  Oncotarget       Date:  2017-01-17

8.  RCSD1-ABL1 Translocation Associated with IKZF1 Gene Deletion in B-Cell Acute Lymphoblastic Leukemia.

Authors:  Shawana Kamran; Gordana Raca; Kamran Nazir
Journal:  Case Rep Hematol       Date:  2015-10-27

9.  Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes.

Authors:  Koichi Takahashi; Feng Wang; Kiyomi Morita; Yuanqing Yan; Peter Hu; Pei Zhao; Abdallah Abou Zhar; Chang Jiun Wu; Curtis Gumbs; Latasha Little; Samantha Tippen; Rebecca Thornton; Marcus Coyle; Marisela Mendoza; Erika Thompson; Jianhua Zhang; Courtney D DiNardo; Nitin Jain; Farhad Ravandi; Jorge E Cortes; Guillermo Garcia-Manero; Steven Kornblau; Michael Andreeff; Elias Jabbour; Carlos Bueso-Ramos; Akifumi Takaori-Kondo; Marina Konopleva; Keyur Patel; Hagop Kantarjian; P Andrew Futreal
Journal:  Nat Commun       Date:  2018-07-10       Impact factor: 14.919

Review 10.  Genomic Analyses of Pediatric Acute Lymphoblastic Leukemia Ph+ and Ph-Like-Recent Progress in Treatment.

Authors:  Agnieszka Kaczmarska; Patrycja Śliwa; Joanna Zawitkowska; Monika Lejman
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.